Latest Cover
Prescriber is the leading UK journal for healthcare professionals focussing on prescribing and medicines management. The journal features articles on all areas of therapeutics and prescribing policy and is fully peer reviewed. The content is relevant and of interest to all prescribers and prescribing policy makers including GPs, pharmacists, nurses and hospital specialists. Access to all content is free to healthcare professionals following registration.Sign up for e-alerts and print copies

Latest News

First drug for all major forms of HCV

The US Food and Drug Administration (FDA) has approved the combination drug of sofosbuvir/velpatasvir (Epclusa) for adults with chronic hepatitis C virus (HCV)...Read more

Thousands denied access to life extending treatment

The first drug to treat Cystic Fibrosis is not recommended for use on the NHS, leaving thousands of patients unable to access treatment.Lumacaftor/ivacaftor...Read more

NHS psoriasis treatment improves quality of life

A new treatment for plaque psoriasis is now available on the NHS.Calcipotriol/betamethasone dipropionate  (Enstilar) is available as a once-daily topical foam...Read more

NHS medical technology fund launches

From April 2017, cost effective medical devices proven to benefit patients will be added to NHS England’s national tariff system, according to NHS England...Read more

Liraglutide reduces risk of cardiovascular events

Liraglutide (Victoza) significantly reduces the risk of major cardiovascular events in adults with type 2 diabetes, according to a study presented at the...Read more

Featured Articles

The expanding role of nurse prescribers
Since the first legislation back in the 1980s, UK nurses have earned increasing powers to prescribe. This article discusses the scope and limitations of nurses’ prescribing role now and in the future.
Click here to view

Research consortium offers new hope for Parkinson’s disease
Until recently, research progress in the field of Parkinson’s disease has been slow compared with other therapeutic areas. However, a new consortium of pharmaceutical companies, academic researchers and charities – the Critical Path for Parkinson’s Consortium – is helping to accelerate the development of new treatments to slow disease progression.
Click here to view

Modern management of juvenile idiopathic arthritis
Many children with juvenile idiopathic arthritis (JIA) experience delays in diagnosis, but evidence suggests that treating early and aggressively leads to better long-term outcomes. This article discusses the recommended treatment options, including both traditional therapies and the newer biological agents.
Click here to view

Web design and marketing agency Leamington Spa